Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective,observational study to evaluate post-approval safety survillance of Tofacitinib in patients with Rheumatoid arthritis: data from US based Corrona Rheumatoid arthritis registry

Next Previous
Trial Profile

A prospective,observational study to evaluate post-approval safety survillance of Tofacitinib in patients with Rheumatoid arthritis: data from US based Corrona Rheumatoid arthritis registry

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Feb 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofacitinib (Primary) ; Disease-modifying antirheumatics
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions

    • Most Recent Events

    • 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism
    • 15 Jun 2019 Results assessing Methotrexate Discontinuation and Dose Decreases after Therapy with Tocilizumab (n=444) presented at the 20th Annual Congress of the European League Against Rheumatism
    • 24 Oct 2018 Results assessing efficacy outcomes between 11 mg QD and 5 mg BID doses (n=334) presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top